Human serum albumin incorporating synthetic heme: Red blood cell substitute without hypertension by nitric oxide scavenging

Eishun Tsuchida, Teruyuki Komatsu, Yasuko Matsukawa, Akito Nakagawa, Hiromi Sakai, Koichi Kobayashi, Makoto Suematsu

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The administration of extracellular, hemoglobin-based oxygen carriers often elicits an acute increase in blood pressure by vasoconstriction. This side effect is now recognized to be due to the depletion of nitric oxide (endothelial-derived relaxing factor) by the extravasuated hemoglobins. We have recently found that the administration of a recombinant human serum albumin (rHSA)-based oxygen carrier involving synthetic tetraphenyporphinatoiron(II) derivative (FeP) (rHSA-FeP) does not induce such hypertensive action, because of its low permeability through the vascular endothelium. The heart rate responses after the rHSA-FeP injection were also negligibly small. Visualization of the intestinal microcirculatory changes clearly revealed the widths of the venule and arteriole to be fairly constant. The entirely synthetic rHSA-FeP becomes a promising material as a new type of red blood cell substitute.

Original languageEnglish
Pages (from-to)257-261
Number of pages5
JournalJournal of Biomedical Materials Research - Part A
Volume64
Issue number2
Publication statusPublished - 2003 Feb 1

Fingerprint

Hemoglobin
Scavenging
Nitric oxide
Heme
Serum Albumin
Nitric Oxide
Blood
Cells
Oxygen
Blood pressure
Hemoglobins
Visualization
Derivatives
Vasoconstriction

Keywords

  • Human serum albumin
  • Hypertension
  • Nitric oxide
  • Red blood cell substitute
  • Synthetic heme

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials

Cite this

Tsuchida, E., Komatsu, T., Matsukawa, Y., Nakagawa, A., Sakai, H., Kobayashi, K., & Suematsu, M. (2003). Human serum albumin incorporating synthetic heme: Red blood cell substitute without hypertension by nitric oxide scavenging. Journal of Biomedical Materials Research - Part A, 64(2), 257-261.

Human serum albumin incorporating synthetic heme : Red blood cell substitute without hypertension by nitric oxide scavenging. / Tsuchida, Eishun; Komatsu, Teruyuki; Matsukawa, Yasuko; Nakagawa, Akito; Sakai, Hiromi; Kobayashi, Koichi; Suematsu, Makoto.

In: Journal of Biomedical Materials Research - Part A, Vol. 64, No. 2, 01.02.2003, p. 257-261.

Research output: Contribution to journalArticle

Tsuchida, E, Komatsu, T, Matsukawa, Y, Nakagawa, A, Sakai, H, Kobayashi, K & Suematsu, M 2003, 'Human serum albumin incorporating synthetic heme: Red blood cell substitute without hypertension by nitric oxide scavenging', Journal of Biomedical Materials Research - Part A, vol. 64, no. 2, pp. 257-261.
Tsuchida, Eishun ; Komatsu, Teruyuki ; Matsukawa, Yasuko ; Nakagawa, Akito ; Sakai, Hiromi ; Kobayashi, Koichi ; Suematsu, Makoto. / Human serum albumin incorporating synthetic heme : Red blood cell substitute without hypertension by nitric oxide scavenging. In: Journal of Biomedical Materials Research - Part A. 2003 ; Vol. 64, No. 2. pp. 257-261.
@article{fd2c52434b1c4a4e98d86c73a5798a32,
title = "Human serum albumin incorporating synthetic heme: Red blood cell substitute without hypertension by nitric oxide scavenging",
abstract = "The administration of extracellular, hemoglobin-based oxygen carriers often elicits an acute increase in blood pressure by vasoconstriction. This side effect is now recognized to be due to the depletion of nitric oxide (endothelial-derived relaxing factor) by the extravasuated hemoglobins. We have recently found that the administration of a recombinant human serum albumin (rHSA)-based oxygen carrier involving synthetic tetraphenyporphinatoiron(II) derivative (FeP) (rHSA-FeP) does not induce such hypertensive action, because of its low permeability through the vascular endothelium. The heart rate responses after the rHSA-FeP injection were also negligibly small. Visualization of the intestinal microcirculatory changes clearly revealed the widths of the venule and arteriole to be fairly constant. The entirely synthetic rHSA-FeP becomes a promising material as a new type of red blood cell substitute.",
keywords = "Human serum albumin, Hypertension, Nitric oxide, Red blood cell substitute, Synthetic heme",
author = "Eishun Tsuchida and Teruyuki Komatsu and Yasuko Matsukawa and Akito Nakagawa and Hiromi Sakai and Koichi Kobayashi and Makoto Suematsu",
year = "2003",
month = "2",
day = "1",
language = "English",
volume = "64",
pages = "257--261",
journal = "Journal of Biomedical Materials Research",
issn = "1549-3296",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Human serum albumin incorporating synthetic heme

T2 - Red blood cell substitute without hypertension by nitric oxide scavenging

AU - Tsuchida, Eishun

AU - Komatsu, Teruyuki

AU - Matsukawa, Yasuko

AU - Nakagawa, Akito

AU - Sakai, Hiromi

AU - Kobayashi, Koichi

AU - Suematsu, Makoto

PY - 2003/2/1

Y1 - 2003/2/1

N2 - The administration of extracellular, hemoglobin-based oxygen carriers often elicits an acute increase in blood pressure by vasoconstriction. This side effect is now recognized to be due to the depletion of nitric oxide (endothelial-derived relaxing factor) by the extravasuated hemoglobins. We have recently found that the administration of a recombinant human serum albumin (rHSA)-based oxygen carrier involving synthetic tetraphenyporphinatoiron(II) derivative (FeP) (rHSA-FeP) does not induce such hypertensive action, because of its low permeability through the vascular endothelium. The heart rate responses after the rHSA-FeP injection were also negligibly small. Visualization of the intestinal microcirculatory changes clearly revealed the widths of the venule and arteriole to be fairly constant. The entirely synthetic rHSA-FeP becomes a promising material as a new type of red blood cell substitute.

AB - The administration of extracellular, hemoglobin-based oxygen carriers often elicits an acute increase in blood pressure by vasoconstriction. This side effect is now recognized to be due to the depletion of nitric oxide (endothelial-derived relaxing factor) by the extravasuated hemoglobins. We have recently found that the administration of a recombinant human serum albumin (rHSA)-based oxygen carrier involving synthetic tetraphenyporphinatoiron(II) derivative (FeP) (rHSA-FeP) does not induce such hypertensive action, because of its low permeability through the vascular endothelium. The heart rate responses after the rHSA-FeP injection were also negligibly small. Visualization of the intestinal microcirculatory changes clearly revealed the widths of the venule and arteriole to be fairly constant. The entirely synthetic rHSA-FeP becomes a promising material as a new type of red blood cell substitute.

KW - Human serum albumin

KW - Hypertension

KW - Nitric oxide

KW - Red blood cell substitute

KW - Synthetic heme

UR - http://www.scopus.com/inward/record.url?scp=0042924431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042924431&partnerID=8YFLogxK

M3 - Article

C2 - 12522812

AN - SCOPUS:0042924431

VL - 64

SP - 257

EP - 261

JO - Journal of Biomedical Materials Research

JF - Journal of Biomedical Materials Research

SN - 1549-3296

IS - 2

ER -